The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Hepatic arterial infusion (HAI) of oxaliplatin with either LV5FU2 or FOLFIRI in patients (pts) with refractory metastatic colorectal cancer (mCRC).
A. Rahal
No relevant relationships to disclose
D. Malka
Consultant or Advisory Role - Roche
Honoraria - Merck Serono; Sanofi
Other Remuneration - Roche
D. Goéré
No relevant relationships to disclose
V. Boige
Consultant or Advisory Role - Pfizer
Honoraria - Merck Serono
Other Remuneration - Merck Serono; Roche
T. De Baere
No relevant relationships to disclose
D. Elias
No relevant relationships to disclose
F. Deschamps
No relevant relationships to disclose
C. Rahal
No relevant relationships to disclose
M. Ducreux
Honoraria - Merck Serono
Research Funding - Roche